Heartache For Novartis As Serelaxin Failure Ups Pressure On Entresto

 
• By Sukaina Virji
  
Generate a summary of this article
Listen to this article
Beta

Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.

Arrows miss target

Novartis AG's relaxin receptor agonist serelaxin (RLX030; recombinant relaxin) – touted as a potential blockbuster by some analysts – has failed in the RELAX-AHF-2 Phase III clinical trial for acute heart failure (AHF). The drug missed both co-primary endpoints of worsening of heart failure and cardiovascular death in the RELAX-AHF-2 study, which had been required by regulators to confirm serelaxin's potential benefits following mixed results from an earlier trial. (Also see "FDA reviewers advise no go for Novartis' serelaxin " - Scrip, 26 March, 2014.)

"We had included the product in our pipeline forecasts at $500m in 2021 and $750m in 2025," admitted Bernstein's Tim...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By Jung Won Shin

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip